DIETRICH JOHN W
DIETRICH JOHN W's purchase track record
DIETRICH JOHN W has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/7/2025 | FDX | $274K | -27.6% | -12.2% | +5.4% |
| 12/28/2023 | FDX | $252K | +14.8% | +17.8% | +14.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
AAR Corp. Expands Aerospace Aftermarket Reach Amid Market Upswing. AAR Corp. has broadened its manufacturing upside and expanded its aerospace aftermarket business, which helped lift the stock after a recent 20.5% decline. Shares jumped after the company announced new aftermarket contracts, and analysts noted a possible trend reversal. The stock is near a key support level of $111.57, and its RSI of 29.5 suggests it may still have room to move higher.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Evercore and Wells Fargo Lower FHN Price Targets to $25. Evercore ISI and Wells Fargo recently lowered their price targets for First Horizon to $25, citing concerns about the bank's net interest income in a rising rate environment. These updates align with the stock trading near its 52-week low, reflecting cautious sentiment among analysts. The average analyst target remains at $27.69, but the recent cuts indicate a more conservative outlook for the near term.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
FedEx eyes record-high Q4 delivery prices and expands digital pharma booking. FedEx expects delivery rates to reach record highs in the fourth quarter, according to a TD Cowen/AFS note. The company says its recent freight‑spin strategy has improved performance, though pricing is still relatively high. It also launched a digital booking platform for European cold‑chain pharmaceutical shipments to make the process smoother for customers.
Transaction History
| AAL | ▲ Buy | Grant | 8,676 | $0 | 7/15/2026 | View on chart |
| AIR | ▲ Buy | Grant | 1,364 | $0 | 6/1/2026 | View on chart |
| FHN | ▲ Buy | Grant | 5,913 | $0 | 5/5/2026 | View on chart |
| FDX | ▲ Buy | Grant | 6,595 | $0 | 6/26/2025 | View on chart |
| AIR | ▲ Buy | Grant | 2,198 | $0 | 6/1/2025 | View on chart |
| FHN | ▲ Buy | Grant | 7,794 | $0 | 5/6/2025 | View on chart |
| FDX | ▲ Buy | Open Market | 1,000 | $274K | 1/7/2025 | View on chart |
| FDX | ▲ Buy | Grant | 3,322 | $0 | 6/27/2024 | View on chart |
| AIR | ▲ Buy | Grant | 1,901 | $0 | 6/1/2024 | View on chart |
| FHN | ▲ Buy | Grant | 9,414 | $0 | 4/29/2024 | View on chart |
| FHN | ▲ Buy | Grant | 2,184 | $0 | 1/31/2024 | View on chart |
| FDX | ▲ Buy | Open Market | 1,000 | $252K | 12/28/2023 | View on chart |
| AIR | ▲ Buy | Grant | 2,426 | $0 | 6/1/2023 | View on chart |
| AIR | ▲ Buy | Grant | 537 | $0 | 3/16/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Analysts Lower AAL Fair Value Amid Rising Fuel Cost Concerns
Analysts have lowered American Airlines’ fair value after reexamining fuel cost assumptions. The recent Goldman Sachs cut to an $11 target reflects the same concern. New regulatory pressure to carry epinephrine on all flights could add to operating costs, while broader airline earnings reports from Delta give context to the sector’s mixed outlook.
Analysts Lower AAL Fair Value Amid Rising Fuel Cost Concerns. Analysts have lowered American Airlines’ fair value after reexamining fuel cost assumptions. The recent Goldman Sachs cut to an $11 target reflects the same concern. New regulatory pressure to carry epinephrine on all flights could add to operating costs, while broader airline earnings reports from Delta give context to the sector’s mixed outlook.